Axelar's AXL1717 to be presented at the American Association of Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida
(Thomson Reuters ONE) -
Stockholm - Sweden - March 29, 2011. Axelar AB today announced that study
results from the Phase I study evaluating AXL1717 for the treatment of squamous
cell lung carcinoma will be presented at the American Association of Cancer
Research annual meeting being held in Orlando, Florida. Axelar is part of the
Karolinska Development portfolio of companies.
Poster presentation (abstract # 1276): "A novel targeted oral Insulin-like
Growth Factor 1 (IGF-1) receptor inhibitor and its implications for patients
with squamous cell lung carcinoma."
* Monday April 4, 2011 from 8:00 a.m. - 12:00 p.m.
* General poster session in exhibit hall A4-C, poster section 12.
* Abstract number 1276
* Lead author: Ekman, S.
For further information, please contact:
Fredrik Röök, VP Business Development, Axelar AB
Phone: +46 (0) 708 67 60 38, e-mail:fredrik.rook(at)axelar.se
TO THE EDITORS
About Axelar
Axelar AB is a Swedish biotech company founded in 2003. The company is
developing insulin-like growth factor-1 (IGF-1) receptor inhibitors for
treatment of cancer and other diseases. Axelar is part of the Karolinska
Development portfolio of companies.www.axelar.se
About AXL1717
Axelar's lead compound, AXL1717 provides a novel treatment regimen for a wide
range of cancers. AXL1717 is the first targeted oral small-molecule IGF-1
receptor inhibitor with no effect on the insulin receptor. AXL1717 is presently
undergoing phase I/II clinical trials and the compound combines a superior
preclinical efficacy against numerous tumors with an excellent tolerability
profile. Most tumor cells are dependent on the IGF-1 receptor signal pathway and
the IGF-1 receptor is therefore regarded as a very promising target for cancer
therapy. To date, there are no IGF-1 receptor inhibitor drugs on the market.
News Release as PDF:
http://hugin.info/144419/R/1501139/436476.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Axelar AB via Thomson Reuters ONE
[HUG#1501139]
Unternehmensinformation / Kurzprofil:
Datum: 29.03.2011 - 13:00 Uhr
Sprache: Deutsch
News-ID 52908
Anzahl Zeichen: 2675
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Axelar's AXL1717 to be presented at the American Association of Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida"
steht unter der journalistisch-redaktionellen Verantwortung von
Axelar AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
